secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001104659-24-036897
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical posts record 2023 net sales of $83.6M; achieves first-ever adjusted EBITDA profit in Q4
--------------------------------------------------------------------------------

- Q4 2023 net sales $22.1M (+14% YoY); Q4 adjusted EBITDA $0.5M vs ($0.6M) in Q4 2022, first positive quarter in company history.
- Full-year 2023 net sales $83.6M (+15% YoY); gross profit $8.7M (+114% YoY); net loss improved 55% to ($8.4M).
- 2024 guidance: net product sales $84-88M (5-10% growth), gross margin 14-16%, and full-year adjusted EBITDA $0-0.5M.
- Amended Innovatus loan: interest rate reduced, maturity extended to Jan 2029; interest-only payments for 30-36 months.
- Acquired Evoqua hemodialysis concentrates assets in July 2023; became leading US liquid bicarbonate supplier.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000110465924036897/0001104659-24-036897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000110465924036897/tm249327d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-036897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer